^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DSP-107
i
Other names: DSP-107, CD47-based dual signaling protein, KAHR-107, DSP107, DSP 107, KAHR 107, KAHR107
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kahr Medical
Drug class:
CD47 inhibitor, CD137 agonist
Related drugs:
1m
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Kahr Medical | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • azacitidine • DSP-107
1m
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=125, Recruiting, Kahr Medical | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type
|
Tecentriq (atezolizumab) • DSP-107
over1year
A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=125, Recruiting, Kahr Medical | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type
|
Tecentriq (atezolizumab) • DSP-107
over2years
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. (PubMed, J Exp Clin Cancer Res)
DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.
Journal
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
Rituxan (rituximab) • DSP-107
Share via
